ALPN News and Press, Alpine Immune Sciences Inc. From 12/21/23

2023-12-21 17:21:38 ET Alpine Immune Sciences ( NASDAQ: ALPN ) said it has amended its 2020 option and license agreement with AbbVie ( ABBV ) for acazicolcept and will be stopping a Phase 2 study for the drug early to allow for early assessment of the data. Alpine said enrol...

-- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus (Synergy) will be stopped to allow for early assessment of data -- -- Final analysis after last patient completes study protocol expected to occur by the end of 2024 -- Alpine Immune Sciences, I...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd An...

2023-11-21 00:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the upcoming Evercore ISI HealthconX Conference, November 28-30,...

--Povetacicept Superior to Wild-Type TACI-Fc and B-cell Depletion in a Preclinical Model of Lupus-- -- Initiation of Phase 2 SLE Study Planned for 2H 2024 -- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovativ...

2023-11-14 16:57:37 ET More on Alpine Immune Sciences Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling Alpine Immune Sciences: Going Strong But For How Long? Alpine Immune Sciences down 1.9%, prices $150M offering Alpine Immune gains ...

-- First clinical data with povetacicept presented at American Society of Nephrology Kidney Week support best-in-class potential and broad pipeline opportunity – -- Company closed an oversubscribed $150 million equity offering to accelerate multiple development activities – ...

-- Phase 2 Study in SLE (Synergy) Ongoing -- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...